Effects of omapatrilat on blood pressure and insulin sensitivity in an animal model of insulin resistance

Blood Pressure

Volumn 10, Issue 3, 2001, Pages 164-169

  Aguilar Salinas, C A ^a   Arellano, S A ^a   Villanueva Sanchez, O ^a   Magos, G A ^a   Guillen Pineda L E ^a   Rodriguez, R ^a   Gomez Perez F J ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Blood pressure; Fosinopril; Insulin resistance; Omapatrilat; Zucker rats

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; GLUCOSE; INSULIN; N (2 MERCAPTOMETHYL 3 PHENYLBUTYRYL)ALANINE; OMAPATRILAT; PLACEBO; TRIACYLGLYCEROL; VASOPEPTIDASE INHIBITOR;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CUFF; DIET RESTRICTION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MOUSE MUTANT; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PARAMETER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT; RAT STRAIN; SYSTOLIC BLOOD PRESSURE; TAIL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FOSINOPRIL; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN RESISTANCE; MALE; MODELS, ANIMAL; OBESITY; PYRIDINES; RATS; RATS, ZUCKER; THIAZEPINES; TRIGLYCERIDES;

EID: 0034761517     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370501753182389     Document Type: Article

References (37)

1. The effect of nisoldipine as compared with enalapril on cardiovascular events in patient with non insulin dependent diabetes and hypertension
2. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial
3. Efficacy of atenolol and captopril in reducing the risk of macrovascular complications in type 2 diabetes (UKPDS 39)
4. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes
5. Carbohydrate metabolism in hypertension: Influence of treatment
6. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection
7. ACE inhibition and glucose transport in insulin-resistant muscle: Roles of bradykinin and nitric oxide
8. Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non insulin dependent diabetes mellitus
9. Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension
10. Lisinopril administration improves insulin action in aged patients with hypertension
11. Insulin sensitivity in normotensive subjects during angiotensin converting enzyme inhibition with fosinopril
12. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme
13. Angiotensin inhibition potentiates the renal response to neutral endopeptidase inhibition in dogs with congestive heart failure
14. Long term effects of BMS-186716 and captopril on ventricular function and remodeling in cardiomyopathic hamsters
15. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril
16. Hormones of the Cardiovascular System
17. Atrial natriuretic peptides inhibit the release of corticotropin-releasing factor-41 from the rat hypothalamus in vitro
18. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Event (FACET) in patients with hypertension and NIDDM
19. Metabolic and hemodynamic effects of Moxonidine in Zucker Diabetic Fatty Rat model of type 2 diabetes
20. Vasopeptidase inhibition: A new concept in blood pressure management
21. The safety and efficacy of omapatrilat in patients with hypertension and renal insufficiency
22. Omapatrilat in elderly patients with isolated systolic hypertension
23. Omapatrilat in hypertensive subjects over 65 years of age: A placebo controlled trial
24. Long term stable administration of omapatrilat demonstrates persistence of antihypertensive efficacy
25. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus
26. Emerging treatments for hypertension: Potential role for vasopeptidase inhibition
27. Omapatrilat compared with lisinopril in treatment of hypertension assessed by ambulatory blood pressure monitoring
28. Effect of omapatrilat and lisinopril on plasma concentration of adrenomedullin in patients with salt sensitive hypertension
29. Omapatrilat-the ups and downs of an exciting but complicated new drug
30. Nonhypoglycemic effects of thialozidinediones
31. The lipid mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men
32. Metabolic effects of long term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: Relationship to angiotensin-converting enzyme inhibition
33. Insulin sensitivity in normotensive subjects during angiotensin converting enzyme inhibition with fosinopril
34. Effects of Enalapril, Losartan and Verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat
35. Imidapril, an angiotensin converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in Zucker fatty rat
36. Effects of acute hyperinsulinemia on plasma atrial and brain natriuretic peptide
37. Insulin blunts the natriuretic action of atril natriuretic peptide in hypertension